In this conversation, the group discusses why motivating diverse patient populations is key to creating appropriately diverse clinical trial populations in NASH and NAFLD. Alicia Staley describes her key principles as “collaboration and building collateral.” Listen as she and the other panelists discuss actions and programs that are key to success, including a primer on what not to include as patient qualification criteria.
TOPICS: Diagnostic Tests, DrugTrial, Global Liver Institute, NAFLD, NASH, Patient Advocacy, population screening, TrialDesign, Medidata, knowRx, patient focused drug development, patient empowerment, GLI Advanced Advocacy Academy
Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast